

Keytruda® (pembrolizumab) – Updated indication, accelerated approval converted to full approval

- On January 25, 2024, the <u>FDA granted</u> full approval of Merck's <u>Keytruda (pembrolizumab)</u>, for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.
- This FDA action converts the accelerated approval of Keytruda for HCC to a full approval and updates the indication.
 - The original accelerated approval was for the treatment of patients with HCC who have been previously treated with sorafenib.
- The approval of Keytruda for the updated indication was based on KEYNOTE-394, a randomized, placebo-controlled, double-blind study conducted in Asia in patients with Barcelona Clinic Liver Cancer (BCLC) Stage B or C HCC, who were previously treated with sorafenib or oxaliplatin-based chemotherapy and who were not amenable to or were refractory to local-regional therapy. The study enrolled 453 patients, and 360 (79%) had active hepatitis B. Patients were randomized to Keytruda or placebo. The main efficacy measure was overall survival (OS). Additional efficacy outcome measures were progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR).
 - Keytruda improved OS in patients with HCC secondary to hepatitis B. Efficacy results in hepatitis B patients are summarized in the table below.

Endpoint	Keytruda	Placebo
OS		
Median in months (95% CI)	13.9 (12.5, 17.9)	13.0 (10.1, 15.6)
Hazard ratio (95% CI)	0.78 (0.61, 0.99)	
PFS		
Median in months (95% CI)	2 (1.4, 2.7)	2.3 (1.4, 2.8)
Hazard ratio (95% CI)	0.78 (0.61, 1.00)	
ORR		
ORR (95% CI)	11% (7, 16)	1.6% (0.2, 5.7)
DOR		
Median in months (range)	23.9 (2.6+, 44.4+)	5.6 (3.0+, 5.6)

- The recommended dose of Keytruda for the treatment of HCC is 200 mg every 3 weeks or 400 mg every 6 weeks, via intravenous infusion, until disease progression, unacceptable toxicity, or up to 24 months.
- Refer to the Keytruda drug label for dosing for all its other indications.

Optum

At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.